Chlorthalidone and HCTZ Impacts on Platelet Activation
Status unconfirmed · Phase 4
Conditions studied: Hypertension
In brief
This will be a randomized, double-blinded, three-period crossover study of platelet activation and aggregation in 30 non-smoking healthy volunteers comparing chlorthalidone (CTD), hydrochlorothiazide (HCTZ), and aspirin (ASA; active control). The study hypothesis is that CTD has different effects on platelet activation and aggregation than HCTZ.
Key facts
- Study ID
- NCT02100462
- Run by
- Creighton University
- People needed
- 30
- Starts
- 2014-03-01
- Expected to finish
- 2016-12-01
- Last updated by the study team
- 2015-12-14
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Men or women age 19 or older
- Not currently taking any routinely scheduled prescription or over the counter medications or herbal supplements
- No use of aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol, dipyridamole, NSAID medications, or herbal supplements within the previous 7 days and able to refrain from use during the study period
- Systolic blood pressure > 110 mmHg and diastolic blood pressure > 60 mmHg
- Non-smoker
You may not qualify if…
- Previous adverse reaction or allergy to HCTZ, CTD, or ASA
- Severe sulfonamide hypersensitivity (anaphylaxis or Stevens-Johnson syndrome)
- Diagnosis of any chronic disease or condition
- History of gout or hyperuricemia
- History of pancreatitis
- History of systemic lupus erythematosus (SLE)
- History of hypokalemia requiring treatment
- Pregnant or planning to become pregnant during the study period
- Breastfeeding
- History of hypotension
- History of gastrointestinal bleeding
Where it is running
- Creighton University — Omaha, Nebraska, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.